CHERRY HILL, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (OTC: VYNT) is providing an update to shareholders regarding its winddown activities pursuant to its Plan of Liquidation and Dissolution following the sale of substantially all of its assets. Vyant Bio’s Board of Directors has filed its Certificate of Dissolution with the State of Delaware with an effective time of 5:00 p.m. on December 29, 2023, after which the Company’s stock will cease trading on the OTC, and the holders of shares of the Company’s common stock will cease to have any rights in respect of that stock, except the right of holders at such time to receive distributions, if any, pursuant to and in accordance with the Plan of Dissolution.
Vyant Bio Provides Update on Winddown Activities
CHERRY HILL, N.J., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (Vyant Bio or Company) (OTC: VYNT) is announcing the results of its special meeting of stockholders on November 1, 2023 (the...
CHERRY HILL, N.J., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (œVyant Bio or œCompany) (OTC: VYNT) announced that it has completed the sale of all or substantially all of the assets of the...
CHERRY HILL, N.J., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (œVyant Bio or œCompany) (OTC: VYNT) announced that its special meeting of stockholders on October 19, 2023 (the œSpecial...
CHERRY HILL, N.J., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (œVyant Bio or œCompany) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the...
CHERRY HILL, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (œVyant Bio or œCompany) (OTC: VYNT), today announced that its special meeting of stockholders on September 28, 2023 (the...
CHERRY HILL, N.J., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (œVyant Bio or œCompany) (OTC: VYNT), today announced that its special meeting of stockholders on September 20, 2023 (the...
NEW ORLEANS and CHERRY HILL, N.J., July 17, 2023 /PRNewswire/ -- AxoSim, Inc., a leader in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc. (OTC: VYNT) (Vyant Bio) today announced that they have entered into a definitive agreement under which AxoSim will acquire the microBrain™-associated assets of Vyant Bio's StemoniX subsidiary. The all-cash transaction is expected to close in the next several months, subject to approval by Vyant Bio's shareholders. The companies also announced that effective immediately, AxoSim will have exclusive and sole distribution rights to market the StemoniX microBrain technology platform to pharmaceutical and biotechnology customers. These rights would terminate in the event the transaction is not consummated.
CHERRY HILL, N.J., May 12, 2023 (GLOBE NEWSWIRE) -- Vyant Bio, Inc. (“Vyant Bio” or “Company”) (Nasdaq: VYNT) is a biotechnology company that incorporates innovative biology and data science to...